Kyle Diamantas leads the market at 43% as the current acting FDA commissioner following Marty Makary’s May 2026 resignation, with reports highlighting his effective management of food policy priorities and growing internal support despite limited prior public health experience. Sara Brenner at 17% reflects her earlier acting commissioner role and deputy experience before shifting to HHS. Brett Giroir, Grace Graham, and Stephen Hahn trail as speculative alternatives amid the administration’s search for a permanent nominee aligned with drug approval reforms and food safety goals. The 12% probability of no announcement by December 31 accounts for Senate confirmation timelines and the deliberate pace of identifying candidates who can rebuild agency trust under HHS oversight.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourKyle Diamantas 36%
No announcement by December 31 14.3%
Brett Giroir 10.2%
Sara Brenner 7.4%
$13,643 Vol.
$13,643 Vol.
31 déc. 2026
Kyle Diamantas
33%
Stephen Hahn
4%
Brett Giroir
13%
Grace Graham
4%
Sara Brenner
7%
No announcement by December 31
14%
Kyle Diamantas 36%
No announcement by December 31 14.3%
Brett Giroir 10.2%
Sara Brenner 7.4%
$13,643 Vol.
$13,643 Vol.
31 déc. 2026
Kyle Diamantas
$2,940 Vol.
33%
Stephen Hahn
$1,539 Vol.
4%
Brett Giroir
$2,559 Vol.
13%
Grace Graham
$3,778 Vol.
4%
Sara Brenner
$2,198 Vol.
7%
No announcement by December 31
$630 Vol.
14%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads the market at 43% as the current acting FDA commissioner following Marty Makary’s May 2026 resignation, with reports highlighting his effective management of food policy priorities and growing internal support despite limited prior public health experience. Sara Brenner at 17% reflects her earlier acting commissioner role and deputy experience before shifting to HHS. Brett Giroir, Grace Graham, and Stephen Hahn trail as speculative alternatives amid the administration’s search for a permanent nominee aligned with drug approval reforms and food safety goals. The 12% probability of no announcement by December 31 accounts for Senate confirmation timelines and the deliberate pace of identifying candidates who can rebuild agency trust under HHS oversight.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Marché ouvert : May 12, 2026, 7:59 PM ET
Volume
$13,643Date de fin
31 déc. 2026Marché ouvert
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads the market at 43% as the current acting FDA commissioner following Marty Makary’s May 2026 resignation, with reports highlighting his effective management of food policy priorities and growing internal support despite limited prior public health experience. Sara Brenner at 17% reflects her earlier acting commissioner role and deputy experience before shifting to HHS. Brett Giroir, Grace Graham, and Stephen Hahn trail as speculative alternatives amid the administration’s search for a permanent nominee aligned with drug approval reforms and food safety goals. The 12% probability of no announcement by December 31 accounts for Senate confirmation timelines and the deliberate pace of identifying candidates who can rebuild agency trust under HHS oversight.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$13,643Date de fin
31 déc. 2026Marché ouvert
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas leads the market at 43% as the current acting FDA commissioner following Marty Makary’s May 2026 resignation, with reports highlighting his effective management of food policy priorities and growing internal support despite limited prior public health experience. Sara Brenner at 17% reflects her earlier acting commissioner role and deputy experience before shifting to HHS. Brett Giroir, Grace Graham, and Stephen Hahn trail as speculative alternatives amid the administration’s search for a permanent nominee aligned with drug approval reforms and food safety goals. The 12% probability of no announcement by December 31 accounts for Senate confirmation timelines and the deliberate pace of identifying candidates who can rebuild agency trust under HHS oversight.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes